E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

PHASE3CompletedINTERVENTIONAL
Enrollment

629

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

June 30, 2008

Conditions
Heartburn
Interventions
DRUG

rabeprazole sodium

Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.

OTHER

Placebo

Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.

Trial Locations (1)

92084

Jeffrey L. Newman, Vista

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00236184 - E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers | Biotech Hunter | Biotech Hunter